- Home
- DERM
as 03-28-2025 4:00pm EST
Journey Medical Corp is a commercial stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm and others.
| Founded: | 2014 | Country: | United States |
| Employees: | N/A | City: | SCOTTSDALE |
| Market Cap: | 107.4M | IPO Year: | 2021 |
| Target Price: | $10.00 | AVG Volume (30 days): | 65.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.72 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.20 - $6.89 | Next Earning Date: | 03-26-2025 |
| Revenue: | $56,134,000 | Revenue Growth: | -29.11% |
| Revenue Growth (this year): | -26.93% | Revenue Growth (next year): | 36.49% |
Stock Insider Trading Activity of Journey Medical Corporation (DERM)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Maraoui Claude | DERM | President & CEO | Mar 11 '25 | Sell | $5.01 | 49,271 | $246,847.71 | 2,003,147 | |
| Maraoui Claude | DERM | President & CEO | Mar 6 '25 | Sell | $5.03 | 40,456 | $203,451.09 | 2,003,147 | |
| Maraoui Claude | DERM | President & CEO | Mar 3 '25 | Sell | $5.12 | 70,556 | $360,761.67 | 2,003,147 | |
| Benesch Joseph | DERM | CFO | Feb 21 '25 | Sell | $5.19 | 1,365 | $7,084.35 | 45,966 |
Latest Journey Medical Corporation News
DERM Breaking Stock News: Dive into DERM Ticker-Specific Updates for Smart Investing
Simply Wall St.
12 hours ago
Journey Medical Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag
Thomson Reuters StreetEvents
a day ago
Q4 2024 Journey Medical Corp Earnings Call
GuruFocus.com
2 days ago
Journey Medical Corp (DERM) Q4 2024 Earnings Call Highlights: Strategic Launch of Emrosi and ...
Zacks
2 days ago
Journey Medical Corporation (DERM) Tops Q4 Earnings Estimates
GlobeNewswire
2 days ago
Journey Medical Corporation Reports Full-Year 2024 Financial Results and Recent Corporate Highlights
GuruFocus.com
3 days ago
Journey Medical Corp (DERM) Q4 2024 Earnings Report Preview: What To Expect
TipRanks
3 days ago
Journey Medical launches Emrosi for the treatment of rosacea
GlobeNewswire
4 days ago
Journey Medical Corporation Launches Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules, 10 mg immediate release and 30 mg extended release) for the Treatment of Rosacea
Compare DERM vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "DERM Journey Medical Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.